Metformina + Sitagliptina Generis Phar

Metformin Hydrochloride, the active ingredient in Metformina + Sitagliptina Generis Phar, is a biguanide presented as an oral tablet for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus, often in combination with sitagliptin, a DPP‑4 inhibitor. The combination targets both hepatic glucose production and incretin pathways to achieve better glycemic management.

GNH USA supplies Metformina + Sitagliptina Generis Phar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including procurement for public and private health systems.

Metformina + Sitagliptina is indicated for type 2 diabetes mellitus, a chronic metabolic disorder requiring glucose‑lowering therapy. - Type 2 diabetes mellitus (initial therapy): lowers HbA1c as part of first‑line treatment. - Type 2 diabetes mellitus (add‑on therapy): provides additional glucose reduction when metformin alone is insufficient. - Type 2 diabetes mellitus (fixed‑dose combination): simplifies regimen and improves patient adherence.

Metformina + Sitagliptina may cause a range of adverse reactions.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Metallic taste in the mouth. - Upper respiratory tract infection symptoms. - Headache. - Mild hypoglycemia when combined with other glucose‑lowering agents.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes. - Acute kidney injury: reduced renal clearance leading to drug accumulation.

Before prescribing Metformina + Sitagliptina, consider the following precautions. - Renal function assessment: evaluate eGFR prior to initiation and periodically thereafter. - Lactic acidosis risk: avoid in patients with severe renal impairment or conditions predisposing to hypoxia. - Pregnancy and lactation: use only if potential benefits justify potential risks. - Drug interactions: review concomitant medications that may affect renal function or increase hypoglycemia. - Monitoring: regularly check HbA1c, renal function, and liver enzymes. - Store at ambient temperature: keep in the original container, protect from moisture.

Metformina + Sitagliptina can interact with several medicines; categorize them by clinical relevance.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal dysfunction and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations, heightening toxicity. - Excessive alcohol intake: amplifies risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: increased risk of hypoglycemia. - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics (loop or thiazide): can affect renal clearance of metformin.